CYMBALTA Drug Patent Profile

When do Cymbalta patents expire, and what generic alternatives are available?

Cymbalta is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in CYMBALTA is duloxetine hydrochloride. There are forty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cymbalta

A generic version of CYMBALTA was approved as duloxetine hydrochloride by AUROBINDO PHARMA LTD on December 11^th, 2013.

Summary for CYMBALTA

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for CYMBALTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CYMBALTA	Delayed-release Capsules	duloxetine hydrochloride	40 mg	021427	1	2012-05-10
CYMBALTA	Delayed-release Capsules	duloxetine hydrochloride	20 mg, 30 mg and 60 mg	021427	16	2008-08-04

US Patents and Regulatory Information for CYMBALTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-001	Aug 3, 2004		DISCN	Yes	No
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-002	Aug 3, 2004		DISCN	Yes	No
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-004	Aug 3, 2004		DISCN	Yes	No

International Patents for CYMBALTA

See the table below for patents covering CYMBALTA around the world.

Country	Patent Number	Title	Estimated Expiration
China	1316904
Portugal	86389	PROCESSO PARA A PREPARACAO DE 3-ARILOXI-PROPANAMINAS 3-SUBSTITUIDAS
Hungary	9502134
Australia	591007

Supplementary Protection Certificates for CYMBALTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0273658	91131	Luxembourg		91131, EXPIRES: 20121218
0273658	3/2005	Austria		PRODUCT NAME: 3-ARYLOXY-3-SUBSTITUIERTE-PROPANAMINE; REGISTRATION NO/DATE: EU/1/04/280/001 - EU/1/04/280/006 20040811
0693282	PA2005001,C0693282	Lithuania		PRODUCT NAME: DULOXETINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/04/280/001, EU/1/04/280/002, EU/1/04/280/003, EU/1/04/280/004, EU/1/04/280/005, EU/1/04/280/006 20040811
0273658	SPC/GB05/003	United Kingdom		PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811

Investment Scenario, Market Dynamics, and Financial Trajectory for CYMBALTA (Duloxetine)

Last updated: February 3, 2026

Summary

Cymbalta (Duloxetine), developed by Eli Lilly and Co., is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. Its market presence has been significant, but recent patent expirations, generic competition, and market shifts influence its investment outlook. This report dissects the current market landscape, key financial drivers, competitive environment, and forecasted trajectory to inform strategic investment decisions.

Overview of CYMBALTA (Duloxetine)

Parameter	Details
Approval Date	August 2004
Indications	MDD, GAD, diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain
Manufacturer	Eli Lilly and Co.
Mechanism of Action	Serotonin-norepinephrine reuptake inhibition
Therapeutic Class	SNRI

Market Size and Revenue Streams

Historical Sales Performance

Year	Global Sales (USD Million)	Notes
2018	2,157	Peak before patent expiry
2019	2,010	Slight decline
2020	1,895	Competitor entry accelerates decline
2021	1,732	Post-patent revenue erosion
2022	1,460	Dominance of generic versions

Revenue Breakdown

Revenue Source	Percentage of Total	Notes
Branded sales (patent-protected)	30%	Mainly in the US, legal exclusivities
Generic competition	65%	Major impact post-2018 patent expiration
New formulations or combinations	5%	R&D pipelines, combination therapies

Market Penetration and Key Markets

• United States: Largest single market; critical for revenue
• Europe: Significant but declining due to generics
• Emerging Markets: Growing access but lower margins

Market Dynamics and Competitive Landscape

Patent Expiry and Generic Competition

Year	Patent Expiration	Impact
2017	August 2017	Transition to generic market in the US
2018	US market patent expiration	Sharp decline in branded sales begins

Major Competitors and Market Share

Competitor	Product	Market Share (2022)	Notes
Generic Duloxetine	Multiple manufacturers	65-70%	Price competition dominates
Effexor (Venlafaxine)	Pfizer, generic options	10-15%	Competes in similar indications
Other SNRI/SSRI drugs	Sertraline, Escitalopram, Venlafaxine	10-15%	Alternative treatments

Regulatory and Market Trends

• Patent expirations continue to erode market exclusivity.
• Pricing pressures escalate globally due to generics.
• Reimbursement shifts favor newer therapies in some regions.
• Pipeline developments are concentrated in combination therapies and new formulations to differentiate.

Financial Trajectory and Investment Outlook

Forecasted Revenue Trends (2023–2028)

Year	Estimated Global Sales (USD Million)	Assumptions
2023	1,200	Continued generic share, slight decline from 2022
2024	950	Increased competition, price erosion
2025	800	Market maturation, emergence of biosimilars or new formulations
2026	700	Potential stabilization with new indications or formulations
2027	700	Plateau due to market saturation
2028	680	Slight decline influenced by market shifts

Profitability and Margin Analysis

Metric	2022 Figures	Projected 2023–2028	Comments
Gross Margin	~60%	55–60%	Margin compression due to generic pricing pressure
Operating Margin	~25%	15–20%	Increased R&D or marketing in pipeline development
R&D Investment	8–10% of revenue	Consistent or rising as pipeline advances	Focus on new formulations, novel combinations, and biomarkers

Key Investment Drivers

• Patent cliff and generic competition reductions
• Launch of new formulations (e.g., extended-release, combination drugs)
• Emerging indications and expanded approvals
• Pricing and reimbursement policies in key markets
• Pipeline innovations affecting future revenues

Comparison with Similar Drugs

Drug	Indications	Patent Status	2022 Revenue (USD Million)	Key Differentiators
Effexor (Venlafaxine)	Depression, GAD	Expired	~1,200	Broader indication profile
Pristiq (Desvenlafaxine)	Depression	Patent expired	~700	Extended release, similar efficacy
Lyrica (Pregabalin)	Neuropathic pain, fibromyalgia	Patent expired	~3,600	Different mechanism, higher revenue
Savella (Milnacipran)	Fibromyalgia	Patent protected	~150	Limited market penetration

Regulatory and Policy Considerations

Policy Area	Impact on CYMBALTA	Notes
Patent Law	Patent cliffs lead to generics entry	Critical to revenue declines post-2018
Pricing Regulation	Price caps in various markets	Affects profitability, especially in Europe and emerging markets
Reimbursement Rates	Favor newer, patent-protected products	May restrict access to post-patent generic drugs
Innovation Incentives	FDA pathways for new indications	Potential for expanded use and lifecycle extension

FAQs

1. What are the key factors affecting Cymbalta's market share?
   Patent expiration, generic competition, pricing pressures, and evolving treatment guidelines are primary factors. Introduction of new formulations or indications could temporarily enhance market share.

2. How does the patent expiry influence Cymbalta's revenue?
   Post-2018, patent expiry led to immediate availability of generics, drastically reducing branded sales and pressuring prices, leading to revenue decline.

3. What is the outlook for Cymbalta's pipeline?
   Eli Lilly explores new formulations, combination therapies, and expanded indications, which could mitigate revenue erosion and provide growth opportunities.

4. Are there new indications that could revive Cymbalta's sales?
   Research into additional emotional and pain-related indications may extend market relevance, but regulatory approval remains uncertain.

5. How does Cymbalta compare to its competitors in the SNRI market?
   While formerly dominant, generic competition has diminished its market share; newer SNRI formulations may offer better efficacy or tolerability, challenging Cymbalta’s positioning.

Key Takeaways

• Market dynamics are heavily influenced by patent expiry, resulting in a sharp decline in revenue since 2018 as generic competition took hold.
• Revenue projections suggest a continued slight decline, with potential stabilization if new formulations or indications gain regulatory approval.
• Competitive landscape favors generic manufacturers, with large market share erosion for branded Cymbalta.
• Investment risks are primarily driven by patent cliffs and reimbursement policies; opportunities may exist in pipeline development.
• Strategic management should focus on innovation, expanding indications, and optimizing pricing strategies to sustain profitability.

References

[1] Eli Lilly Annual Reports (2018–2022).
[2] IQVIA MIDAS Database (2022).
[3] FDA Drug Approvals and Patent Data (2023).
[4] Market Research Reports on SNRI Drugs (2022–2023).
[5] Health Policy and Reimbursement Frameworks, OECD Reports (2022).

---

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice.